Sanofi teams with non-prof­it on a land­mark new drug for sleep­ing sick­ness

The EMA has of­fered its en­dorse­ment for fex­inida­zole, which is billed as the first all-oral drug for sleep­ing sick­ness.

The Drugs for Ne­glect­ed Dis­eases ini­tia­tive han­dled the clin­i­cal tri­al work for the drug, with its part­ners at Sanofi han­dling the ap­pli­ca­tion part. A group of 7 Eu­ro­pean coun­tries packed the $62.5 mil­lion de­vel­op­ment cam­paign for the drug, with some added sup­port com­ing from the Bill & Melin­da Gates Foun­da­tion and Médecins Sans Fron­tières.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.